Fulfilling the Promise of the Food Safety Modernization Act: The Importance of Stakeholder Engagement
Recently, I had the good fortune to fill in for an FDA colleague on a panel entitled, “Assuring the Safety of Imported Food” at the National Food Policy Conference, which is organized by the Consumer Federation of America.
Participants at the conference included a broad spectrum of activists, public officials, nutrition professionals, farm and food industry representatives, and scientists who are interested in agriculture, food and nutrition policy. The Food and Drug Administration Food Safety Modernization Act (FSMA) was one of the key areas of focus at the conference.
Even though I was called from the audience to participate unexpectedly in the panel, I hoped my role as Vice-Chair of FDA’s FSMA Imports Implementation Team would stand me in good stead. Fortunately, the other panelists spoke first, which gave me the chance to organize my thoughts.
My fellow panelists, Caroline Smith DeWaal, from the Center for Science in the Public Interest, Mike Robach, from Cargill, and Eduardo Santos from Allen F. Johnson and Associates spoke eloquently on the challenges and opportunities that the imports provisions of FSMA represent to consumers, industry, and other countries. They identified various key issues associated with FSMA implementation including the costs associated with implementation, training, capacity building in exporting countries, and ensuring both accountability and fairness.
In addition to emphasizing some of the main features of the FSMA imports provision, I discussed how FDA is approaching the task of developing over 50 deliverables mandated by FSMA, our outreach strategy, the importance of making sure our actions are consistent with our WTO obligations, and the overarching need for stakeholder involvement.
The main message I hoped to leave with the audience was the importance of their role as stakeholders in providing information, practical scenarios, and data as we proceed with FSMA implementation. FDA’s significant and ongoing effort at early engagement via public meetings has already provided FDA with many useful insights. I encouraged stakeholders to use the “notice and comment” process to continue to provide information and feedback in response to upcoming proposed regulations.
The task before us is huge. Currently, there are over 160 countries exporting hundreds of thousands of FDA regulated food products to the U.S. How do we collectively assure safety? How do the import provisions consider domestic provisions? FSMA provides the framework to harness leading business global food safety practices, consumer expectations and importer practicalities, with agency standards and oversight. We have a long way to go before we fully implement FSMA, but we have the platform on which to build and I am confident that we are up to the task at hand.
During the conference, Secretary of Agriculture Tom Vilsac, CDC Director Thomas Frieden, and FDA Commissioner Margaret Hamburg highlighted the work of their respective agencies in addressing nutrition and food safety issues. They each echoed the importance of food safety and the public imperative for stakeholders to work together to optimize the safety and nutritional adequacy of our food supply.
Dr. Hamburg started her speech with, “Will Rogers liked to say that most political promises are about as solid as applesauce… (and FDA regulates applesauce!) But some promises are just too important not to keep… like the promise that our food supply will be safe for every American.”
Each of us has a stake in bringing this promise to life. The National Food Policy Forum was a terrific opportunity to be inspired, to strengthen our resolve, and to keep the stakeholder momentum moving ever forward.
Acting Deputy Director for Regulatory Affairs, Center for Food Safety and Applied Nutrition
Senior Advisor for International Affairs, Office of Foods, Office of the Commissioner
U.S. Food and Drug Administration.
Did you know that you can report problems that you have had with drugs and other medical products to the FDA? Did you know that MedWatch can send safety alerts directly to you, as soon as they appear on the web site?
The FDA will host a webinar “FDA’s MedWatch System: How to Report Adverse Events”. The featured speaker, Brenda Rose Pharm.D., a Health Programs Coordinator in FDA’s Office of Special Health Issues will give an overview and answer questions about how to report adverse events to MedWatch.
The free 30 minute webinar will be held Thursday, October 20th at 11 AM ET.
There are a limited number of spots available for the webinar. Materials from the webinar will also be made available on the FDA website following the presentation.
The best way to get into the Gulf of Maine in August is to jump feet first. So, “jump feet first” is what I did this week on my first day as chief medical officer and director of outbreaks for the FDA Coordinated Outbreak Response and Evaluation (CORE) Network.
CORE, with a dedicated multi-disciplinary staff, is meant to provide a streamlined, integrated approach to how FDA not only responds to human and animal foodborne illness outbreaks, but how we improve surveillance and post-response efforts, to apply lessons learned and prevent future outbreaks. When an outbreak happens, the CORE staff will decide the strategy of FDA’s response, working closely with the FDA field staff, and coordinate with other key federal, state and local food safety agencies.
After 28 years as Maine’s state epidemiologist, the management of outbreaks is vital to me, but even more important is learning from them in order to prevent or minimize future outbreaks. That’s what public health’s emphasis on preventive medicine is all about.
So, when asked what I wanted to do on my first day, I said hear firsthand from some of our partners, both inside FDA and outside.
I was able to briefly introduce myself to a crucial component of the CORE Network – the FDA Regional and District offices, during one of their regular weekly conference calls. CORE is already coordinating and will continue to work closely with the Districts during outbreak response and related activities, building on the best of what FDA has done in the past, and finding ways together to improve and streamline our efforts going forward.
I was also able to visit with the director of the Office of Crisis Management for the Agency, which will continue to play the lead role in responding to natural disasters and other incidents. I toured the Emergency Operations Center and talked with the director and staff to assure them that CORE will continue to work closely with this crucial office in the future.
Key consumer groups, including two organizations representing foodborne illness victims and their families, also shared their insights with me and my FDA colleagues. Two of the members of these groups spoke movingly of the deaths of their children from contaminated food and how they vowed to use their experiences to improve food safety for all American families.
As a mother of four children, I listened and tried to imagine the grief they have experienced. Having investigated numerous foodborne outbreaks at the State level, I have experienced the frustration of being unable to identify the “culprit”; or, when successful, wondering how food contamination could ever have occurred in this modern world; and wishing that the “lessons learned” from the outbreak could have been translated into effective preventive recommendations and policy. After hearing their stories, the “why” of food safety has never been clearer for me.
This commitment to food safety was also the theme of a call with industry representatives who spoke of the critical knowledge they can bring to bear in times of a foodborne illness outbreak.
For instance, two of the large trade associations representing the produce industry spoke about the wealth of information they have on produce and how they want to make certain FDA has access to and is able use this valuable data they have before, during and after an outbreak.
A large group representing retailers echoed this commitment to sharing information throughout our conversation, as well as making certain the industry’s “knowledge factor” is used in outbreak response. We all reiterated the importance “of learning in retrospect” from outbreaks, and I shared with them that this was a lesson I had learned early on in my work in preventive medicine.
Meetings with new colleagues at FDA and on the calls with some of our stakeholders also gave me an opportunity to reflect on the historic shift taking place in food safety. The FDA Food Safety Modernization Act squarely puts in place the public health principle of prevention as the foundation of all our food safety efforts.
It’s an historic shift not only for those of us in government, but also for industry. And prevention is key for all of us, as Commissioner Hamburg and I agreed when I had the opportunity to chat with her the next morning. It is especially important in today’s world, where our food supply is global as well as local.
Bracing and exhilarating would be my words for that first day – just like that Gulf of Maine. And it’s what I was hoping for.
Dr. Kathleen F. Gensheimer, M.D., M.P.H.,
Chief Medical Officer
The best way to get into the Gulf of Maine in August is to jump feet first.
Today, FDA is releasing 8 new draft proposals in a report entitled “Food and Drug Administration Transparency Initiative: Draft Proposals for Public Comment to Increase Transparency By Promoting Greater Access to the Agency’s Compliance and Enforcement Data.”
These draft proposals are focused on making FDA’s compliance and enforcement data more accessible and user-friendly, and they are part of our ongoing efforts to increase the transparency of FDA’s operations and decision-making.
In developing these draft proposals, FDA met with the Environmental Protection Agency (EPA) and the Department of Labor (DOL), both of which have well-developed and well-regarded enforcement data websites (www.epa-echo.gov and http://ogesdw.dol.gov, respectively). At these meetings, EPA and DOL shared their insights to help us learn from, and build upon, their experiences. Like FDA, EPA and DOL recognize that transparency can drive good behavior and promote regulatory compliance.
We invite the public to comment on FDA’s draft proposals, and to review the Agency’s progress in implementing other action items and draft proposals related to the Transparency Initiative at:
Lisa M. Dwyer, J.D.
Senior Policy Advisor and Transparency Initiative Coordinator
Do you know that in 2010 there were a record number of shortages of prescription drugs, and that in 2011, FDA continues to see an increasing number of shortages, especially those involving older sterile injectable drugs?
As part of FDA Basics, FDA is hosting a webinar where you can learn how the agency helps reduce the impact of drug shortages for patients and our nation’s health care system. Captain Valerie Jensen, R.Ph., Associate Director for FDA’s Center for Drug Evaluation and Research’s (CDER’s) Drug Shortage Program, will discuss the extent of the current drug shortage issue and the importance of communication among FDA, drug manufacturers, health professionals, and the public, in helping to reduce its impact on public health.
The free 30 minute webinar will be held Friday, September 30m, at 11 am ET.
There are a limited number of spots available for the webinar. Materials from the webinar will also be made available on the FDA website following the presentation.
Last week, farmers from across the North and South forks of Suffolk county Long Island showed a group of us from the U.S. Departments of Agriculture and Health and Human Services, the Food and Drug Administration (FDA), and the New York State Department of Agriculture and Markets the incredible diversity of their farms and the challenges FDA faces in writing a “produce safety” rule.
Bob Nolan, who farms 30 acres with his son and uncle, invited us because he heard that we had walked the rows of other fresh fruit and vegetable farms across the country. In fact, this was the 14th state we visited in the last year or so. We have seen the orchards of Oregon, the vast vegetable fields of California, Amish farms in Ohio, irrigation-dependent produce operations in Texas, vegetable farms in Delaware, North Carolina family farms, and Florida tomato fields to name just a few.
And each time, we have come away with new insights from the farmers and their families about how they are already addressing produce safety concerns, what they expect from an FDA rule, and the challenges of maintaining their way of life.
Our Long Island tour was a microcosm of the diversity we have seen across the country. Organized by Cornell extension agent Sandy Menasha and Long Island Farm Bureau executive director Joe Gergela, the tour of seven farms ranged from small to large, conventional to organic, first-generation farmer to twelfth generation.
Let’s face it, the first question a federal official gets asked on a farm is as blunt as the summer day is long: Why are you here? Mike Taylor, the FDA deputy commissioner for foods, has a pretty good answer: If we’re going to get this produce safety rule right, we need to learn from you.
That’s it in a nutshell. While FDA and its colleagues at USDA bring to the table scientific and public health expertise, we all know that farms are very much the real world of soil, air and water open to the elements 24/7 and worked by humans and animals. Farmers can inform us from their experience and practices.
Just see the different perspectives shared with us last week: the first-generation organic farm of the Garden of Eve; the 225-acre Ed Zilnicki and Sons’ potato farm; Nolan’s 30-acre Deer Farms devoted to leafy greens; the “agritainment” and “u-pick” farms like Hank’s Pumpkin Town, Harbes’ Family Farm, and the Milk Pail; and the farm stand run by Jim and Jennifer Pike.
And we got to hear loud and clear what the farmers expect from the FDA. “I can’t hire a food safety guy. I am the food safety guy,” Bob Nolan said. Hank Kraszewski wants the produce safety rule to be “crystal clear.” Tell farmers straight out, “What do I have to do,” he said. Record-keeping can’t become burdensome for small farmers like themselves, Eve Kaplan-Walbrecht and Jim Pike told us.
Farmers are also thirsty to learn more. Horse manure is a time-honored soil amendment for the sandy fields of Long Island. How can they apply it safely, they want to know.
And, while we heard that while farmers get it about food safety, they also want us to get it about the economic realities they face. Several had struggled in the ‘90s when wholesale potato farming became less profitable and they moved to other commodities and on-farm retail sales.
Successful produce safety is possible if farmers and food safety officials work together, listening to each other and learning from each other.
Sharon Natanblut, Senior Advisor to the Deputy Commissioner for Foods, FDA
Science is the backbone of everything we do at FDA. Which is why today’s release of the agency’s Strategic Plan for Regulatory Science is a significant next step in the agency’s Regulatory Science Initiative, originally announced in October, 2010. We are releasing the plan along with a podcast and a consumer article to make it easier for everyone to join this conversation about regulatory science and understand what this plan really means.
“As new discoveries yield increasingly complex products,” says FDA Commissioner Margaret A. Hamburg, M.D. “this strategic plan ensures that our experts are equipped to make science-based decisions resulting in sound regulatory policy. It positions us to foster innovation through better science without compromising our high safety standard.”
This plan calls for a sweeping modernization of the science used in developing and evaluating products critical to the nation’s health, economy and security. It recognizes the important role the agency must play in fostering innovations in the marketplace today to address the public health challenges of tomorrow.
All around us we see evidence that new technologies are creating unprecedented opportunities to prevent and cure disease as well as to grow our high tech economy. As my colleague and FDA’s Chief Scientist Dr. Jesse Goodman says: “This plan will help turn advances in science into products that benefit people, and help FDA assure that happens more quickly and safely. It is win-win-win, because it will help the public, the agency and developers of new products.”
This plan signals clearly the agency’s intent to work collaboratively with our colleagues in academia and industry to enhance the process for developing and evaluating promising new products and novel materials emerging from fields such as cell therapies, tissue engineering, genomics and personalized medicine, and through use of advanced computing and information technology.
As we move forward, we welcome ideas and comments. We are inviting our partners, domestic and international, and the public to join the conversation as we take the steps necessary to advance and target the best regulatory science to help meet the nation’s highest public health priorities and medical needs.